Relax, just breath...

The first step in your quest to increase Healthspan and Lifespan.   

On March 18, during the special, Winfrey talked about how using one of these weight-loss drugs (she did not say which) changed her life and opened her eyes to the reality that obesity is a disease, rather than a choice. “All these years, I thought all of the people who never had to diet were just using their willpower, and they were for some reason stronger than me,” Winfrey said.

After taking medication, however, she realized that she thought about food differently than people who had no trouble keeping weight off. Her brain was working against her. "You weren't thinking about the food! You weren't obsessing about it!" she said. “That is the big thing I learned."

GLP-1 drugs were linked to reduced Depression and Anxiety in people with diabetes, compared with people who were not taking GLP-1 medications:

This group of medications is based on related compounds, all of which are glucagon-like peptide-1 (GLP) receptor agonists that mimic the natural GLP-1 intestinal hormone.  In doing so, they produce insulin after eating, helping to reduce blood sugar. They also slow the emptying of the stomach and promote a sensation of being full, leading to a reduction in appetite.

The most well-known GLP-1 drugs, Wegovy and Ozempic, are based on semaglutide.  Other GLP-1 agonist compounds tested in the study are liraglutide, dulaglutide, and exenatide, as well as tirzepatide that mimics a second intestinal hormone, gastric inhibitory polypeptide, or GIP, in addition to GLP-1.

People with diabetes who were taking Semaglutide were 45% less likely to be diagnosed with depression, and 44% less likely to have anxiety.

For people who do not have diabetes, only semaglutide was associated with a reduction in depression and anxiety, compared to people who were not on GLP-1 medications.

The study analyzed patient records for 3,081,254 people with diabetes and 929,174 without diabetes, who were taking the drugs for weight loss.